What Do We Know About Sex and Gender Differences in Disease Risk and Treatment? A Science-Based Overview

Women suffer heart attacks differently than men—often with atypical symptoms that doctors have been trained to overlook. Yet for decades, medical research treated the male body as the default, enrolling far fewer women in clinical trials and leaving physicians unprepared to recognize disease in half the population. This systematic blindness has had real consequences: women are more likely to be misdiagnosed with anxiety when they’re actually having a heart attack, and they’re more likely to die from sudden cardiac events. The question that emerges is both simple and profound: how many other diseases are we understanding only halfway?

Today, sex and gender differences in disease risk and treatment have become one of the most important frontiers in precision medicine. Researchers are discovering that biological sex—determined by chromosomes and hormones—and gender identity and social factors influence everything from autoimmune disease susceptibility to drug metabolism to psychiatric outcomes. Understanding these differences is not merely academic; it’s reshaping how drugs are tested, how diseases are diagnosed, and how personalized medicine is being built. As the field matures, it promises to improve outcomes for everyone, but only if medicine can overcome its long history of treating diversity as an afterthought.

What Is Sex and Gender Differences in Disease Risk and Treatment?

Sex and gender differences in disease risk and treatment refers to the measurable variations in how people of different sexes and genders experience, develop, and respond to illness and medical interventions. Biological sex—defined by chromosomes (XX versus XY), reproductive anatomy, and hormone levels—creates physiological differences that affect susceptibility to certain diseases and responses to medications. Gender, by contrast, encompasses social roles, behavioral expectations, and identity, which influence health behaviors, stress levels, access to care, and clinical outcomes. The interaction between these two dimensions means that disease patterns and treatment efficacy cannot be understood by looking at biology or society in isolation.

The modern recognition of sex differences in disease dates back to the 1980s, when researchers began noticing that women’s cardiovascular disease presented differently than men’s, yet diagnostic criteria had been developed almost exclusively in male populations. In 1993, the U.S. National Institutes of Health issued a groundbreaking mandate requiring researchers to include women in clinical trials and analyze data by sex. Before this directive, the assumption had been that biological sex was merely a variable to be controlled for or ignored—a profound methodological error that affected everything from cardiology to psychiatry. This shift marked the beginning of a slow but accelerating movement toward sex and gender-conscious medicine.

What the Research Shows

The biological mechanisms underlying sex differences in disease are multifaceted and operate at every level of physiology. The most obvious is the influence of sex hormones: estrogen, progesterone, and testosterone don’t just regulate reproduction—they modulate immune function, inflammation, bone metabolism, cardiovascular tone, and brain chemistry. Women’s immune systems, primed by estrogen, mount faster and more vigorous antibody responses, which protects against infections but makes them three to nine times more likely to develop autoimmune diseases like lupus and rheumatoid arthritis. Men’s testosterone, conversely, has immunosuppressive properties, leaving them more vulnerable to certain infections but less prone to autoimmune conditions. Beyond hormones, sex chromosomes themselves—the X and Y—carry genes that influence disease risk independently of hormone effects, and women’s two X chromosomes create a complex genetic landscape that men simply do not possess.

Consider the example of depression and anxiety disorders. Women experience these conditions at roughly double the rate of men, a difference that appears early in adolescence and persists across cultures. The straightforward explanation—that women simply talk about their feelings more—crumbles under scrutiny. Instead, research reveals a constellation of factors: hormonal fluctuations across the menstrual cycle and menopause affect neurotransmitter systems like serotonin; women’s greater exposure to trauma, particularly sexual assault; social pressures around appearance and achievement; and biological stress responses that interact with these social factors. The brain imaging studies show that men and women activate different neural networks when processing emotional stimuli, suggesting that the very architecture of emotional processing may differ. This is not to say that depression in women is “just hormones” or “all in their head,” but rather that we cannot understand women’s mental health without integrating biological, psychological, and social dimensions.

What This Means for Patients and Science

The practical implications of sex and gender differences in disease are already reshaping clinical medicine. Drug metabolism differs significantly between sexes: women tend to have smaller body sizes, higher body fat percentages, and different patterns of hepatic enzyme activity, meaning they often require lower doses or respond differently to the same medications as men. The antibiotic ciprofloxacin, for instance, reaches higher blood concentrations in women and is more likely to cause tendon rupture in female patients—a risk that went unrecognized for years because trial populations were predominantly male. Women are also more likely to experience adverse drug reactions overall, yet dosing guidelines have historically been based on average male physiology. In cardiology, the recognition that women’s heart attacks present with different symptoms—fatigue, shortness of breath, and jaw pain rather than crushing chest pressure—has led to updated diagnostic criteria and improved survival rates when emergency departments apply sex-specific diagnostic approaches.

Cancer treatment exemplifies how sex and gender awareness is transforming outcomes. Breast cancer incidence is higher in women (though men do get it), while lung cancer strikes male smokers more frequently, but women who smoke are paradoxically at higher risk for the disease. Colorectal cancer rates are rising in younger women but declining in men, a pattern that researchers attribute to differences in screening utilization, reproductive factors, and possibly sex-specific carcinogenic mechanisms. Treatment responses also differ: some chemotherapy agents show better efficacy in women, while others work better in men, and hormonal therapies like tamoxifen for breast cancer function only because cancer cells in women are driven by estrogen pathways that don’t operate in male cancers. Precision oncology now requires sex-stratified analysis of clinical trial data to optimize treatment algorithms.

Recent Breakthroughs in Sex and Gender Differences in Disease Risk and Treatment

The past three years have witnessed a acceleration in sex and gender-informed research. In 2022, the FDA expanded its guidance on sex as a biological variable in drug development, requiring more rigorous analysis of sex differences in pharmacokinetics and pharmacodynamics during clinical trials. Simultaneously, large-scale genomic studies have identified sex-specific genetic risk factors for common diseases: variants on the X chromosome that increase Alzheimer’s disease risk in women but not men, and autosomal genetic variants whose effects are modulated by sex hormones in sex-specific ways. Neuroscience has particularly benefited, with research revealing that women and men show different patterns of neuroinflammation in neurodegenerative diseases, suggesting that anti-inflammatory therapies might need to be tailored by sex. Additionally, the recognition of Long COVID’s sex-specific presentation—women report higher rates and different symptom clusters—has prompted mechanistic investigations into how viral infections interact with female immune physiology and reproductive hormones.

Researchers are now investigating how gender identity and social determinants layer onto biological sex to create additional health disparities. Transgender individuals face elevated risks for mental health conditions, cardiovascular disease, and certain cancers, driven by the complex interplay of discrimination stress, barriers to healthcare, and the physiological effects of gender-affirming hormone therapy. Emerging work is examining how these individuals’ transition status affects disease susceptibility and drug response, a frontier that has been almost entirely absent from medical knowledge until very recently. The field is also grappling with fundamental questions: Can we develop truly personalized medicine that accounts for both biological sex and gender identity? How do we design clinical trials that are both representative and scientifically rigorous?

Why Sex and Gender Differences in Disease Risk and Treatment Matters for the Future

The integration of sex and gender into medicine is not a niche concern—it’s central to the promise of precision medicine itself. If we claim to tailor treatment to individual characteristics, then ignoring half the population’s biology is logically incoherent and practically harmful. As artificial intelligence and machine learning increasingly guide clinical decision-making, training these algorithms on sex-balanced datasets becomes critical; an AI trained predominantly on male patient data will perpetuate and amplify existing biases. The economic stakes are enormous: suboptimal treatment due to sex-specific oversight costs healthcare systems billions annually in avoidable adverse events, hospitalizations, and missed diagnoses. Beyond economics, there’s a moral dimension: medicine’s long history of treating women as secondary research subjects reflects and reinforces broader gender inequalities, and correcting this injustice is both ethically necessary and scientifically productive.

Yet significant challenges remain. Enrolling sufficient numbers of women and gender minorities in clinical trials requires confronting logistical barriers—childcare, work schedules, distrust rooted in historical abuses of research—and the scientific complexity of hormonal variation introduces variability that some researchers view as a problem rather than an opportunity to understand nature. Funding for sex and gender-specific research remains proportionally small, and many medical schools still teach human anatomy and physiology using frameworks that treat male biology as normal and female biology as a deviation. The integration of gender identity and social factors alongside biological sex requires interdisciplinary collaboration that many institutions are not structured to support. Moving forward will demand not just individual scientific breakthroughs, but systemic change in how medicine is funded, taught, and practiced.

Key Takeaways

• Sex and gender differences profoundly shape disease risk, presentation, and treatment response across nearly every medical condition, yet medicine historically ignored these variations by treating male biology as the default.
• Biological sex hormones and sex chromosomes create distinct immune responses, drug metabolism pathways, and physiological vulnerabilities; women’s stronger immune activation protects against infection but increases autoimmune disease risk, while men face opposite tradeoffs.
• The most promising application of this knowledge is precision medicine that tailors drug doses, diagnostic criteria, and treatment selection based on both biological sex and gender identity, already improving outcomes in cardiology and oncology.
• Despite the FDA’s 1993 mandate to include women in trials, the field remains in early stages; many drugs have not been studied adequately in women, and the intersection of sex with race, ethnicity, and socioeconomic status remains under-researched.
• Integrating sex and gender into medicine is both a scientific imperative—necessary for accurate understanding of human biology—and a justice imperative, correcting decades of harm caused by medical research that treated diversity as an afterthought.